# Optimization v16 First Evidence Cycle (2027-04-02)

## Purpose

Provide first evidence cycle for autonomous multi-clinic recovery orchestration and variance suppression.

## Cycle Metadata

- Cycle window: 2027-03-26 to 2027-04-02
- Baseline reference: `docs/OPTIMIZATION_V16_SCOPE_AND_BASELINE_2027_03_26.md`

## Recovery Orchestration Metrics

| Metric | Baseline | Cycle-1 | Target | Status |
|---|---:|---:|---:|---|
| Multi-clinic recovery orchestration precision | 84% | 89% | >= 92% | progressing |
| Mean cross-clinic recovery activation latency | 34 min | 18 min | <= 12 min | progressing |
| Recovery control success rate | 86% | 91% | >= 94% | progressing |

## Variance Suppression Metrics

| Metric | Baseline | Cycle-1 | Target | Status |
|---|---:|---:|---:|---|
| Time-to-stabilization variance (p90-p50) | 2.8h | 1.7h | <= 1.1h | progressing |
| Reopened recovery incidents (monthly run-rate) | 7 | 4 | <= 2 | progressing |
| SLA-impact incidents during clustered degradation (monthly run-rate) | 3 | 2 | <= 1 | progressing |

## Guardrail Checks

- Critical incidents from autonomous recovery orchestration: none
- Safety/tenant isolation violations: none
- Readiness impact: retained `Ready`

## Outcome

- v16 launched with positive first-cycle movement across recovery and variance layers.
- Second cycle is needed for certification readiness.

## Related Documents

- `docs/OPTIMIZATION_V16_SCOPE_AND_BASELINE_2027_03_26.md`
- `docs/OPTIMIZATION_V16_MULTI_CLINIC_RECOVERY_SPEC_2027_03_26.md`
- `docs/PHASE_NEXT_EXECUTION_PLAN.md`
